$ATNM ph3 trial at 50% enrollment: 29 patents (78%) at lomab -B arm  evaluated for the primary Endpoint vs 5patents (13%) at control arm evaluated for the Primary Endpoint:it’s 87% failure on control arm . Great results so far. $jnj $nvs $sny $azn $abbv $amgn @StanTradingMan https://t.co/COOPYt2pKx